Compare Abeona Therapeutics Inc (ABEO) vs EPR Properties (EPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs EPR Properties — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while EPR Properties trades at $59.63 (market cap $4.58B). The key difference: EPR Properties is far larger — about 12.3× Abeona Therapeutics Inc's market cap, and EPR Properties pays a 6.22% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EPR | |
|---|---|---|
Market Cap | $373.32M | $4.58B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $61.21 |
52-Week Low | $4.17 | $48.71 |
Enterprise Value | $228.22M | $7.64B |
Dividend Yield | — | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EPR Properties trades at $59.21, up 0.19% today, with a bullish technical signal supported by moving averages. The REIT shows strong profitability with a 39.93% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.26 versus $0.76 expected. Recent news highlights a $315 million Six Flags acquisition and inclusion on J.P. Morgan's July Focus List (247 Wallst, 2026-07-07).
Outlook remains positive with a consensus price target of $63.00, offering 6.4% upside. Key risks include reliance on experiential assets like theaters amid economic sensitivity, while the 6.2% dividend yield provides income support. Earnings on July 29, 2026, will be critical for validating growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
